- Home
- CURV vs PLX Comparison
CURV vs PLX Comparison
Compare CURV & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- PLX
- Stock Information
- Founded
- CURV 2001
- PLX 1993
- Country
- CURV United States
- PLX United States
- Employees
- CURV N/A
- PLX N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURV Consumer Discretionary
- PLX Health Care
- Exchange
- CURV Nasdaq
- PLX Nasdaq
- Market Cap
- CURV 185.4M
- PLX 164.2M
- IPO Year
- CURV 2021
- PLX 1998
- Fundamental
- Price
- CURV $1.64
- PLX $2.50
- Analyst Decision
- CURV Hold
- PLX Strong Buy
- Analyst Count
- CURV 5
- PLX 1
- Target Price
- CURV $3.03
- PLX $15.00
- AVG Volume (30 Days)
- CURV 648.2K
- PLX 822.2K
- Earning Date
- CURV 09-04-2025
- PLX 11-13-2025
- Dividend Yield
- CURV N/A
- PLX N/A
- EPS Growth
- CURV N/A
- PLX N/A
- EPS
- CURV 0.03
- PLX 0.08
- Revenue
- CURV $1,068,099,000.00
- PLX $61,948,000.00
- Revenue This Year
- CURV N/A
- PLX $14.53
- Revenue Next Year
- CURV N/A
- PLX $75.77
- P/E Ratio
- CURV $56.06
- PLX $32.28
- Revenue Growth
- CURV N/A
- PLX 62.79
- 52 Week Low
- CURV $1.62
- PLX $0.99
- 52 Week High
- CURV $7.19
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CURV 33.71
- PLX 75.47
- Support Level
- CURV $1.63
- PLX $1.52
- Resistance Level
- CURV $1.80
- PLX $2.12
- Average True Range (ATR)
- CURV 0.09
- PLX 0.12
- MACD
- CURV 0.01
- PLX 0.05
- Stochastic Oscillator
- CURV 3.03
- PLX 80.97
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.